- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00228449
Peginesatide for Anemia in Chronic Hemodialysis Patients
December 19, 2012 updated by: Affymax
A Phase 2, Open-label, Multi-center, Sequential, Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Peginesatide Administered Intravenously for the Maintenance Treatment of Anemia in Chronic Hemodialysis Patients
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This was a Phase 2, multicenter, open-label, sequential, dose-finding trial designed with up to 12 treatment cohorts of 15 participants per cohort.
Each participant received an intravenous dose of peginesatide administered once every 4 weeks (Q4W) for a total of 6 doses.
Dosage regimens varied by cohort.
Participants were followed for a minimum of 42 days after the last administration of peginesatide.
Study Type
Interventional
Enrollment (Actual)
165
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35213
- Research Facility
-
-
Arkansas
-
Pine Bluff, Arkansas, United States, 71603
- Research Facility
-
-
California
-
Los Angeles, California, United States, 90095
- Research Facility
-
Mountain View, California, United States, 94041
- Research Facility
-
-
Florida
-
Lauderdale Lakes, Florida, United States, 33313
- Research Facility
-
Pembroke Pines, Florida, United States, 33028
- Research Facility
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
- Research Facility
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Research Facility
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Research Facility
-
-
New York
-
New York, New York, United States, 10128
- Research Facility
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Research Facility
-
-
Tennessee
-
Nashville, Tennessee, United States, 37205
- Research Facility
-
-
Texas
-
San Antonio, Texas, United States, 78215
- Research Facility
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Research Facility
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant is informed of the investigational nature of this study and has given written, witnessed informed consent in accordance with institutional, local, and national guidelines;
- Males or females ≥ 18 years of age. Pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening; those who are sexually active must practice a highly effective method of birth control for at least 4 weeks prior to study start, and must be willing to continue contraception until at least 4 weeks after the last dose of study drug. A highly effective method of birth control is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence (only acceptable if practiced as a life-style and not acceptable if one who is sexually active practices abstinence only for the duration of the study) or vasectomized partner;
- Clinically stable on hemodialysis for ≥6 months prior to study drug administration;
- Urea clearance/volume (Kt/V) ≥ 1.2 within the 4 weeks prior to study drug administration;
- Epoetin alfa maintenance therapy of ≥ 60 and ≤ 375 U/kg/wk continuously prescribed for 8 weeks prior to study drug administration. In the last 3 weeks prior to study drug administration, variation in prescribed total weekly dose must be ≤ 25% from the mean of the last three prescribed total weekly doses;
- Three mid- or end-of-week hemoglobin values of ≥ 10.0 and ≤ 12.5 g/dL in the 3 weeks prior to study drug administration with ≤ 1.2 g/dL difference between the three values;
- One serum ferritin level ≥ 100 micrograms per liter (μg/L) or one transferrin saturation ≥ 20% or one reticulocyte hemoglobin content (CHr) ≥ 29 picograms within 4 weeks prior to study drug administration;
- One serum folate level above the lower limit of normal during the 4 weeks prior to study drug administration;
- One vitamin B12 level above the lower limit of normal during the 4 weeks prior to study drug administration;
- Weight ≥ 45 kilograms (kg) within the 4 weeks prior to study drug administration;
- One white blood cell count ≥ 3.0 x 10^9/L within 4 weeks prior to study drug administration; and
- One platelet count ≥ 100 x 10^9/L and ≤ 500 x 10^9/L within 4 weeks prior to study drug administration.
Exclusion Criteria:
- Known intolerance to erythropoiesis stimulating agents;
- History of antibodies to erythropoiesis stimulating agents or history of pure red cell aplasia;
- Known intolerance to parenteral iron supplementation;
- Red blood cell transfusion within 12 weeks prior to study drug administration;
- Hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all types, etc.);
- Known hemolysis;
- Chronic, uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.);
- C-reactive protein greater than 30 mg/L within the 4 weeks prior to study drug administration;
- Moderate or significant infection within 2 weeks prior to study drug administration;
- Known coagulation disorder based on clinical context and laboratory [activated partial thromboplastin time (aPTT) or international normalized ratio (INR)] results;
- Temporary (untunneled) dialysis access catheter;
- Uncontrolled or symptomatic secondary hyperparathyroidism;
- Poorly controlled hypertension within the 4 weeks prior to study drug administration, per the Investigator's clinical judgment (e.g., systolic ≥ 170 mm Hg or diastolic ≥ 100 mm Hg on repeat readings);
- Any history of multiple significant drug allergies;
- History of severe or unstable reactive airway disease within the previous 10 years;
- Epileptic seizure in the 6 months prior to screening;
- Chronic congestive heart failure (New York Heart Association Class IV);
- High likelihood of early withdrawal or interruption of the study (e.g., myocardial infarction, severe or unstable coronary artery disease, stroke, respiratory, autoimmune, neuropsychiatric, or neurological abnormalities, liver disease including active hepatitis B or C, active HIV disease, or any other clinically significant medical disease or conditions in the prior 6 months that may, in the Investigator's opinion, interfere with assessment or follow-up of the patient);
- Evidence of malignancy within the past 5 years (except non-melanoma skin cancer which is not an exclusion criterion);
- Life expectancy < 12 months;
- Anticipated elective surgery during the study period; and
- Previous exposure to any investigational agent within 6 weeks prior to administration of study drug or planned receipt during the study period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Conversion from epoetin alfa to peginesatide with a conversion factor (CF) of 0.033: peginesatide dose administered intravenously once every 4 weeks (Q4W) for a total of up to 6 doses.
No transition period between epoetin treatment and start of peginesatide treatment.
|
Other Names:
|
Experimental: Cohort 2
Conversion from epoetin alfa to peginesatide with a CF of 0.041: peginesatide dose administered intravenously Q4W for a total of 6 doses.
No transition period between epoetin treatment and start of peginesatide treatment.
|
Other Names:
|
Experimental: Cohort 3
Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses.
No transition period between epoetin treatment and start of peginesatide treatment.
|
Other Names:
|
Experimental: Cohorts 4 and 9
Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses.
With transition period between epoetin treatment and start of peginesatide treatment.
|
Other Names:
|
Experimental: Cohort 5
Conversion from epoetin alfa to peginesatide with a CF of 0.066: peginesatide dose administered intravenously Q4W for a total of 6 doses.
With transition period between epoetin treatment and start of peginesatide treatment.
|
Other Names:
|
Experimental: Cohort 6
Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa .
Doses were administered intravenously Q4W for a total of 6 doses.
With transition period between epoetin treatment and start of peginesatide treatment.
|
Other Names:
|
Experimental: Cohorts 7 and 8
Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa dose.
Doses were administered intravenously Q4W for a total of 6 doses.
No transition period between epoetin treatment and start of peginesatide treatment.
|
Other Names:
|
Experimental: Cohorts 10 and 11
Conversion from epoetin alfa to peginesatide with fixed peginesatide starting doses of 4, 6, 12 or 16 mg based on total weekly doses of epoetin alfa.
Doses were administered intravenously Q4W for a total of 6 doses.
No transition period between epoetin treatment and start of peginesatide treatment.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average weekly hemoglobin and hemoglobin change from baseline
Time Frame: Baseline to Week 27
|
Baseline to Week 27
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of participants with hemoglobin within 1.0 gram per deciliter (g/dL) above or below baseline
Time Frame: Baseline to Week 25
|
Baseline to Week 25
|
Percentage of participants who maintain hemoglobin within 9.5-13.0 g/dL
Time Frame: Baseline to Week 25
|
Baseline to Week 25
|
Percentage of participants who maintain hemoglobin within 11.0-13.0 g/dL
Time Frame: Baseline to Week 25
|
Baseline to Week 25
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Affymax, Affymax, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2005
Primary Completion (Actual)
May 1, 2007
Study Completion (Actual)
May 1, 2007
Study Registration Dates
First Submitted
September 27, 2005
First Submitted That Met QC Criteria
September 27, 2005
First Posted (Estimate)
September 29, 2005
Study Record Updates
Last Update Posted (Estimate)
December 21, 2012
Last Update Submitted That Met QC Criteria
December 19, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AFX01-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Cornell UniversityUniversity of California, Los AngelesCompletedPregnancy Anemia | Newborn; AnemiaUnited States
-
Peking Union Medical College HospitalRecruiting
Clinical Trials on peginesatide
-
TakedaAffymaxTerminated
-
AffymaxCompletedAnemia | Chronic Kidney Disease | Chronic Renal FailureUnited Kingdom, Poland
-
AffymaxCompletedAnemia | Chronic Kidney Disease | Chronic Renal FailureBulgaria, Romania, United Kingdom
-
AffymaxTerminatedAnemia | Chronic Kidney Disease | Chronic Renal FailureBulgaria, Romania, Poland, United Kingdom
-
AffymaxTerminatedAnemia | Chronic Kidney Disease | Chronic Renal FailureUnited States
-
AffymaxTerminatedAnemia | Chronic Kidney Disease | Chronic Renal FailureUnited Kingdom
-
AffymaxCompletedCancer | Chemotherapy Induced AnemiaCzech Republic, Poland, United Kingdom
-
AffymaxCompletedCancer | Anemia | Chronic Kidney Disease | Chronic Renal FailureUnited Kingdom
-
AmgenTerminated
-
TakedaCompletedAnemia | Chronic Kidney Disease | Pure Red Cell Aplasia | Chronic Renal FailureUnited Kingdom, France, Germany